|
|
 |
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Tumor Board Reviewing the Use of PSMA PET in the Care of Patient with Gleason 4+5=9, GG 5 with Seminal Vesicle Invasion Prostate Cancer
|
|
Alicia Morgans, MD, MPH, Heather Jacene, MD, Paul Nguyen, MD, and Adam Kibel, MD
|
| In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 57 year old man with a history of coronary artery disease and Barrett's esophagus. is presented, evaluated, and his treatment plan addressed. |
|
|
|
|
|
|
|
|
|
|
|
|
Tumor Board Reviewing the Use of PSMA PET in Prostate Cancer - Gleason 4+4=8 GG 4, 12 of 12 Cores, High Risk Localized Disease
|
|
Alicia Morgans, MD, MPH, Heather Jacene, MD, Paul Nguyen, MD, and Adam Kibel, MD
|
| In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 62-year-old man with a history of hypertension.
|
|
|
|
|
|
|
|
|
|
|
|
|
Tumor Board Reviewing the Use of PSMA PET in Prostate Cancer -Gleason 3+4=7, GG 2 (left) Gleason 3+3=6 GG 1 (right), Notable Lymph Node Enlargement
|
|
Alicia Morgans, MD, MPH, Heather Jacene, MD, Paul Nguyen, MD, and Adam Kibel, MD
|
| In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 65-year-old man with a history of stage IV marginal zone lymphoma with a PSA of 4.53 in December of 2021.
|
|
|
|
|
|
|
|
|
|
|
|
|
Tumor Board Reviewing the Use of PSMA PET in Patient with Gleason 4+5=9, GG 5 Disease, Bone Scan Demonstrated Mild Uptake Prostate Cancer
|
|
Alicia Morgans, MD, MPH, Heather Jacene, MD, Paul Nguyen, MD, and Adam Kibel, MD
|
| In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 72-year-old male with no past medical history is presented. He has been followed for some time at this point. His PSA in December 2021 was 8.44. His repeat PSA in Feb 2022 was 7.61 and his DRE was notable for having a left-sided firm nodule.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
